Business Wire

Cymulate Reveals Next-level AI Automation for Threat Exposure Validation

18.2.2025 15:00:00 CET | Business Wire | Press release

Share

The company introduces first-of-a-kind automated remediation to eliminate threat exposure, optimize controls and mitigate validated security gaps

Cymulate, the leader in threat exposure validation, today announced the next evolution of the company’s flagship security validation platform. As a pioneer and market leader for breach and attack simulation (BAS) and automated red teaming, Cymulate continues to innovate with automation and artificial intelligence (AI) to deliver the most advanced and easiest-to-use threat exposure validation on the market. At a time when attackers are deploying more advanced tactics than ever, the Cymulate Exposure Validation Platform leverages the power of AI to give every blue and red teamer the automation and accessibility to validate and remediate threat exposure and optimize security.

Exposure validation helps organizations go further than traditional solutions like BAS and automated penetration testing. By embracing the CTEM strategy, security teams can validate their exposure according to their defined threat scope, prioritize contextually according to their specific security strategy, and mobilize while continuously and automatically remediating gaps.

“Security leaders recognize that they need to rapidly address the most exploitable threats in a continuous fashion. Cymulate is bringing first-to-market innovation and automation in our Exposure Validation Platform so security teams can fix their biggest gaps and improve defensive posture before it’s too late,” said Avihai Ben-Yossef, Co-founder and CTO, Cymulate. “We’ve made technologies like attack simulation and automated red teaming easy to implement with actionable findings. Customers are seeing results that reduce noise, clarify decision making and increase the ROI of cyber defense investments.”

The Cymulate Exposure Validation Platform allows security teams to validate their controls alongside potential threats and response tactics, determining which threats are most risky and generating a remediation strategy that prioritizes those exposures first and automates control optimization. Innovative new features include:

  • An AI-powered agent that guides blue teamers and red teamers to create the most impactful validation for their focus – from best practices to industry-specific threats to detailed attack chains from the latest threat intel
  • Streamlined attack simulations that create easier assessments across the MITRE ATT&CK kill chain for all environments, including the most comprehensive library of cloud and Kubernetes attack scenarios
  • A new attack scenario workbench designed to create comprehensive validation assessments from a library of more than one million attack actions or custom scenarios
  • Modular and dynamic assessments that help test for new threats

A key aspect of the Cymulate Exposure Validation Platform is an elevation in the outcome that allows actionable and vendor-specific remediation. Security teams can use their existing stack to manually add optimization rules. Cymulate then automatically pushes these rules to the security controls and automates the entire remediation process.

“The Cymulate Exposure Validation Platform makes advanced security testing fast and easy. When it comes to building custom attack chains, it’s all right in front of you in one place. You can access the full Cymulate library or build your own attack actions,” said Mike Humbert, Cybersecurity Engineer at Cymulate customer Darling Ingredients Inc. “As you start to click and filter, you have the ability to refine what you’re testing, schedule the assessment and drill down to results.”

To learn more about the Cymulate Exposure Validation Platform, visit www.cymulate.com.

About Cymulate

Cymulate, the leader in security and exposure validation, provides the single source of truth for threat exposure and the actions required to close security gaps before attackers can exploit them. More than 1,000 customers worldwide rely on the Cymulate platform to baseline their security posture and strengthen cyber resilience with continuous discovery, validation, prioritization, and guided remediation of security weaknesses. Cymulate automates advanced offensive security testing to validate controls, threats, and attack paths. As an open platform, Cymulate integrates with existing security and IT infrastructure and drives the workflows of the exposure management process. For more information, visit www.cymulate.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218739287/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Reports Third Quarter 2026 Results3.11.2026 22:30:00 CET | Press release

Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026Raising Low-End of Full Year 2026 Financial Guidance RangesRecently Completed $500M Share Repurchase AuthorizationFood Ingredients Divestiture Progressing Well and On Track to Close by End of Second Quarter 2027 IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modes

2026–2027 World Branding Awards Honours Global “Brand of the Year” Winners at Hampton Court Palace3.11.2026 21:00:00 CET | Press release

The World Branding Awards returned to honour the brands that continue to set the benchmark for excellence. The 2026–2027 World Branding Awards Ceremony took place at the iconic Hampton Court Palace, marking the 21st edition of the awards. Set within the grandeur of a historic venue, the prestigious event brought together guests from across the globe for a memorable celebration. The evening was hosted by the acclaimed BBC presenter, Hannah Gray, and was further enriched by a keynote presentation from renowned speaker Adrian Webster. Earning a World Branding Awards remains a highly distinguished achievement. Winners are determined through a rigorous evaluation process encompassing brand valuation, consumer market research, and public online voting. This year, over 105,000 consumers took part in the voting process, and more than 2,000 brands from 62 countries were nominated. Of these, less than 10 brands from each country were declared the “Brand of the Year” across the Global, Regional,

Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 19:05:00 CET | Press release

Located in one of the world’s most prestigious hospitality corridors, the acquisition of the 308-key hotel represents a major milestone in the firm’s international growth. Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisi

SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 16:52:00 CET | Press release

His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year

BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release

Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye